Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NeoGenomics, Inc. - Common Stock (NQ:NEO)

17.13 -0.25 (-1.44%)
Delayed Quote Updated: 9:57 AM EST, Nov 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NeoGenomics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
News headline image
5 revealing analyst questions from NeoGenomics’s Q3 earnings call
NeoGenomics delivered an 11.4% year-over-year revenue increase in Q3, surpassing Wall Street’s expectations. Management emphasized that clinical revenue grow... 
Via StockStory
Topics Earnings
News headline image
NEO Q3 deep dive: product mix shift and margin expansion drive robust oncology testing growth
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) announced better-than-expected revenue in Q3 2026, with sales up 11.4% year on year to $209.3 ... 
Via StockStory
News headline image
What NeoGenomics (NEO) Said on Its Q3 Earnings Call ↗
NeoGenomics (NASDAQ:NEO) reported third-quarter revenue growth of 11% year over year, led by continued expansion in next-generation sequencing, or NGS, testing, while raising its full-year revenue and... 
Via MarketBeat
Topics Earnings
News headline image
NeoGenomics (NEO) Q3 2026 Earnings Call Transcript ↗
NGS revenue surged 29% as management raised full-year guidance. 
Via The Motley Fool
Topics Earnings
NeoGenomics (NASDAQ:NEO) Posts In-Line Q3 Revenue and Above-Consensus EPS ↗
Via Chartmill
NeoGenomics (NASDAQ:NEO): Quality Stock After Q2 Earnings Beat and Raised Guidance ↗
Via Chartmill
Topics Earnings
News headline image
NeoGenomics’s (NASDAQ:NEO) Q3 2026 sales beat estimates
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) reported Q3 2026 results beating Wall Street’s revenue expectations, with revenue up 11.4% yea... 
Via StockStory
Topics Earnings
News headline image
NeoGenomics Reports Third Quarter 2026 Results
From NeoGenomics, Inc.
Via Business Wire
News headline image
Earnings to watch: NeoGenomics (NEO) reports Q3 results tomorrow
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) will be reporting earnings this Wednesday after market close. Here’s what investors should kno... 
Via StockStory
Topics Artificial Intelligence
News headline image
NeoGenomics Expands Indica Labs Partnership to Scale AI-Powered Digital Pathology
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics to Report Third Quarter 2026 Financial Results on October 28, 2026
From NeoGenomics, Inc.
Via Business Wire
News headline image
3 Small-Cap Stocks with Questionable Fundamentals
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in th... 
Via StockStory
News headline image
Why NeoGenomics (NEO) Stock Is Up Today
What Happened? Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) jumped 3.6% in the pre-market session after the company announced an ... 
Via StockStory
Topics Regulatory Compliance
News headline image
NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan
From NeoGenomics, Inc.
Via Business Wire
News headline image
3 Healthcare Stocks We’re Skeptical Of
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva... 
Via StockStory
News headline image
3 Reasons NEO is Risky and 1 Stock to Buy Instead
What a time it’s been for NeoGenomics. In the past six months alone, the company’s stock price has increased by a massive 138%, reaching $19.30 per share. Th... 
Via StockStory
Topics Bankruptcy Supply Chain
News headline image
NeoGenomics Highlights NGS, MRD Growth Strategy at Morgan Stanley Conference ↗
NeoGenomics (NASDAQ:NEO) executives outlined the company’s strategy to expand its role in community-based precision oncology, emphasizing growth in next-generation sequencing, minimal residual disease... 
Via MarketBeat
News headline image
1 Unpopular Stock That Deserves a Second Chance and 2 We Turn Down
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t... 
Via StockStory
Topics Economy
News headline image
A Look Back at Testing & Diagnostics Services Stocks’ Q2 Earnings: NeoGenomics (NASDAQ:NEO) Vs The Rest Of The Pack
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at NeoGenomics (NASDAQ:NEO) and ... 
Via StockStory
News headline image
NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring
From NeoGenomics, Inc.
Via Business Wire
News headline image
3 Unprofitable Stocks Walking a Fine Line
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th... 
Via StockStory
News headline image
3 Stocks Under $50 with Open Questions
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However... 
Via StockStory
News headline image
3 Healthcare Stocks with Questionable Fundamentals
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not on... 
Via StockStory
News headline image
Why NeoGenomics (NEO) Stock Is Up Today
What Happened? Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) jumped 15.8% in the afternoon session after the company reported seco... 
Via StockStory
News headline image
3 of Wall Street’s Favorite Stocks with Questionable Fundamentals
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember... 
Via StockStory
News headline image
NeoGenomics Q2 Earnings Call Highlights ↗
NeoGenomics (NASDAQ:NEO) raised its full-year 2026 revenue and adjusted EBITDA guidance after reporting second-quarter revenue growth that exceeded its prior outlook, led by higher-value clinical... 
Via MarketBeat
Topics Earnings
News headline image
NeoGenomics’s (NASDAQ:NEO) Q2 CY2026: Beats On Revenue
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 11.2% year on... 
Via StockStory
News headline image
NeoGenomics Reports Second Quarter 2026 Results
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics (NEO) Q2 Earnings Report Preview: What To Look For
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) will be announcing earnings results this Tuesday afternoon. Here’s what you need to know. NeoG... 
Via StockStory
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.